Literature DB >> 21808420

Tramadol-induced respiratory depression in a morbidly obese patient with normal renal function.

Thrivikrama P Tantry1, Dinesh Kadam, Pramal Shetty, Karunakara K Adappa.   

Abstract

Entities:  

Year:  2011        PMID: 21808420      PMCID: PMC3141172          DOI: 10.4103/0019-5049.82667

Source DB:  PubMed          Journal:  Indian J Anaesth        ISSN: 0019-5049


× No keyword cloud information.
Sir, Among opioids, tramadol hydrochloride is considered safer than other opioids with respect to its respiratory effects. Dose of tramadol in post-operative patient is up to 250 mg intravenous (i.v.) in initial hour and 600 mg in 24 h.[1] The metabolite of tramadol, O-desmethyl tramadol, (+ODT) has been shown to have an affinity for m opioid receptors (200 times) than that of parent drug and is responsible for analgesia. Tramadol-induced respiratory depression was reported previously in patients with altered renal function.[2] We report such an event in a morbidly obese patient but with normal renal and hepatic functions who received tramadol in clinical doses. A 50-year male, weighing 143 kg (BMI: 50.7 kg/m2), ASA 2 classification, was without any co-morbidity was scheduled for surgery for thigh reduction-plasty [Figure 1]. Nonsmoker nonalcoholic patient with good exercise tolerance reported two uneventful previous surgeries two years ago. He had no history suggestive of obstructive sleep apnoea (OSA) syndrome. Patient had normal renal, liver, cardiovascular function tests. Though pulmonary function tests [Figure 2] were suggestive of early minimal small air way obstruction, after consultation with pulmonologist, it was concluded as adequate. Pre-operative arterial blood gas (ABG) showed pH of 7.347, pCO2 of 55.5 mmHg, pO2 of 73.2 and saturation of 90%.
Figure 1

Morbidly obese patient under anaesthesia for thigh reduction plasty

Figure 2

Preoperative pulmonary function testing curves. (FVC of 75% of predicted, FEV1 of 68% of predicted, FEF25-75 of 33% of predicted and FVV1/FVC ratio of 90% of predicted)

Morbidly obese patient under anaesthesia for thigh reduction plasty Preoperative pulmonary function testing curves. (FVC of 75% of predicted, FEV1 of 68% of predicted, FEF25-75 of 33% of predicted and FVV1/FVC ratio of 90% of predicted) Operating table width was adjusted with additional supports to accommodate hugely built patient. Anaesthesia was induced with fentanyl (150 μg i.v), inj. Propofol (2.5 mg/kg) and succynylcholine (1.5 mg/kg). Sevoflurane-vecuronium-fentanyl (150μg) was used for maintenance. During the uneventful surgery, patient received three units of whole blood, inj. diclofenac sodium 75 mg (i.m). Extubation was uneventful. In the first hour of post-operative period, patient complained severe pain at the operating site. Inj. tramadol 200 mg i.v. was advised and ordered to repeat 8th hourly. Four hours later, patient had adequate pain relief. Second dose of tramadol was administered at 8th hour. Patient was found increasingly drowsy and further tramadol injection was omitted. Patient became unresponsive at 17th hour with sluggish low respiratory rate breathing. ABG showed pH of 6.989, pCO2 of 121.4 mmHg, pO2 of 57.1 mmHg, HCO3 of 28.6 mmol/l and SpO2 of 65%. Emergency intubation was done and mechanical ventilation was started. Inj. Naloxone 0.4 mg i.v. was administered. Subsequently, patient was conscious with adequate mechanical ventilation. ABG parameters improved further. Patient was extubated at 28th hour. In clinical practice, respiratory depression by tramadol is extremely rare.[3] Previous studies shown unaltered end-tidal CO2 changes or respiratory functions with tramadol usage in contrast to injection morphine[4] or pethedine[5] in spontaneously breathing patients. Further, the respiratory rate, arterial O2 and CO2 tensions were found normal in spontaneously breathing patients following upper abdominal surgeries who received epidural tramadol.[6] Teppema et al.[7] observed dose dependent respiratory depression due to tramadol in cats in doses 1-4 mg/kg and highlight the similar possibility in humans in the early postoperative period when residual anaesthetic effects still existing. However, our patient had dose of 1.5 mg/kg and the respiratory effects were observed in late post operative period where anaesthetic effects are ruled out. Our patient had minimally altered but adequate pulmonary functions. Preoperative ABG showed minimally increased CO2 levels, a significant increase in CO2 level and unresponsiveness followed tramadol injections suggesting the possibility of respiratory depression by tramadol. Should the primary cause of respiratory depression be due to pulmonary insufficiency, then patient would have developed respiratory failure in the early post operative period itself when the residual anaesthetic effects still persist. Our patient had excellent recovery from anaesthesia. Conscious patient with complete cognitive and neuromuscular recovery usually need further sedation (and paralysis) for elective mechanical ventilation. Further, respiratory function was unaffected by the surgical incision. Thus, elective mechanical ventilation was not considered. Respiratory depression following iatrogenic tramadol overuse can occur in individuals carrying CYP2D6 duplication (ultrarapid metabolisers, UM).[8] These patients display increased enzyme activity for tramadol, resulting highly increased transformation to active metabolite (+)ODT. However, Asian population have the lowest incidence of 0.5%-2.5% of the CYP2D6 UM genotype, compared to other continents, and the possibility of having such a genotype in our patient could be rare. Routine screening tests for UM genotyping (by polymerase chain reaction) may not be economically feasible, which is a limiting factor to investigate further in our clinical settings.
  7 in total

Review 1.  Obesity in anaesthesia and intensive care.

Authors:  J P Adams; P G Murphy
Journal:  Br J Anaesth       Date:  2000-07       Impact factor: 9.166

Review 2.  Remifentanil and tramadol.

Authors:  D J Duthie
Journal:  Br J Anaesth       Date:  1998-07       Impact factor: 9.166

3.  Comparison of respiratory effects of tramadol and pethidine.

Authors:  P Tarkkila; M Tuominen; L Lindgren
Journal:  Eur J Anaesthesiol       Date:  1998-01       Impact factor: 4.330

4.  Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.

Authors:  Siew Hua Gan; Rusli Ismail; Wan Aasim Wan Adnan; Wan Zulmi
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

5.  A comparison of epidural tramadol and epidural morphine for postoperative analgesia.

Authors:  A Baraka; S Jabbour; M Ghabash; A Nader; G Khoury; A Sibai
Journal:  Can J Anaesth       Date:  1993-04       Impact factor: 5.063

6.  Tramadol: pain relief by an opioid without depression of respiration.

Authors:  M D Vickers; D O'Flaherty; S M Szekely; M Read; J Yoshizumi
Journal:  Anaesthesia       Date:  1992-04       Impact factor: 6.955

7.  Respiratory depression by tramadol in the cat: involvement of opioid receptors.

Authors:  Luc J Teppema; Diederik Nieuwenhuijs; Cees N Olievier; Albert Dahan
Journal:  Anesthesiology       Date:  2003-02       Impact factor: 7.892

  7 in total
  5 in total

1.  All-Cause Mortality Associated with Tramadol Use: A Case-Crossover Study.

Authors:  Sohyun Jeong; Ha Jin Tchoe; Junqing Li; Ju-Young Shin
Journal:  Drug Saf       Date:  2019-06       Impact factor: 5.606

2.  Fentanyl, rather than Tramadol: A cause of respiratory depression.

Authors:  Ghansham Biyani; Sadik Mohammed; Pradeep Bhatia
Journal:  Indian J Anaesth       Date:  2012-01

3.  Acute tramadol poisoning and its clinical and laboratory findings.

Authors:  Hamid Reza Rahimi; Kambiz Soltaninejad; Shahin Shadnia
Journal:  J Res Med Sci       Date:  2014-09       Impact factor: 1.852

4.  Doing without codeine: why and what are the alternatives?

Authors:  Franca Benini; Egidio Barbi
Journal:  Ital J Pediatr       Date:  2014-02-11       Impact factor: 2.638

Review 5.  When the Safe Alternative Is Not That Safe: Tramadol Prescribing in Children.

Authors:  Frédérique Rodieux; Laszlo Vutskits; Klara M Posfay-Barbe; Walid Habre; Valérie Piguet; Jules A Desmeules; Caroline F Samer
Journal:  Front Pharmacol       Date:  2018-03-05       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.